Evidence mapPaperPMID 30869182Full record

Trial reportDiabetes, obesity & metabolism2019

Effects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trial.

Andrew P Demidowich, Jordan A Levine, Ginikanwa I Onyekaba, Shahzaib M Khan, Kong Y Chen, Sheila M Brady, Miranda M Broadney, Jack A Yanovski

2 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02153983 phase1 / phase2completednot on this map

Pilot Study of the Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome

TypeinterventionalSponsorEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Ran2014 to 2018Enrolled77ConditionsObesity, Metabolic DiseaseArmsColchicine 0.6Mg Cap, Placebo capsules given, Colchicine 0.6Mg Tab
NCT05017571 phase2completednot on this mapstarted 2021, after this paper: background citation

COLSIO Trial: Phase II Randomized, Controlled Trial of Colchicine to Suppress Inflammation and Improve Insulin Resistance in Adults and Adolescents With Obesity

TypeinterventionalSponsorEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Ran2021 to 2025Enrolled152ConditionsObesity, Insulin Resistance, InflammationArmsColchicine, Placebo
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Clinical observations on arthroscopic removal of urate deposits in the knee: a seven-case series.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2025
    Article
  11. Review
  12. Inflammation and resolution in obesity.Nature reviews. Endocrinology · 2025 · on this map
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Role of inflammation in diabetic cardiomyopathy.Therapeutic advances in endocrinology and metabolism · 2022
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Andrew P DemidowichSection on Growth and Obesity, Division of Intramural Research (DIR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland.ORCID 0000-0002-5925-1117
Jordan A LevineSection on Growth and Obesity, Division of Intramural Research (DIR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland.
Ginikanwa I OnyekabaSection on Growth and Obesity, Division of Intramural Research (DIR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland.
Shahzaib M KhanSection on Growth and Obesity, Division of Intramural Research (DIR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland.
Kong Y ChenEnergy Metabolism Section, Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, Maryland.
Sheila M BradySection on Growth and Obesity, Division of Intramural Research (DIR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland.
Miranda M BroadneySection on Growth and Obesity, Division of Intramural Research (DIR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland.
Jack A YanovskiSection on Growth and Obesity, Division of Intramural Research (DIR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland.ORCID 0000-0001-8542-1637
National Institutes of Health · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

Physiology, Psychology, and Genetics of ObesityZIAHD000641 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI YANOVSKI, JACK A. · 2009 to 2025
$24.8M
Intramural NIH HHS Z99 HD999999Intramural NIH HHS ZIA HD000641
6 · The paper itself

Abstract

aimTo evaluate the efficacy and safety of colchicine for improving metabolic and inflammatory outcomes in people with obesity and metabolic syndrome (MetS). MATERIALS AND

methodsAdults with obesity and MetS, but who did not have diabetes, were randomized to colchicine 0.6 mg or placebo capsules twice daily for 3 months. The primary outcome was change in insulin sensitivity (S

resultsOf 40 participants randomized (21 colchicine, 19 placebo), 37 completed the trial. Compared with placebo, colchicine significantly reduced C-reactive protein (P <0.005), erythrocyte sedimentation rate (P <0.01), white blood cell count (P <0.005), and absolute neutrophil count (P <0.001). Change in S

conclusionsThis pilot study found colchicine significantly improved obesity-associated inflammatory variables and showed a good safety profile among adults with obesity and MetS who did not have diabetes. These results suggest a larger, adequately powered study should be conducted to determine whether colchicine improves insulin resistance and other measures of metabolic health in at-risk individuals.

Indexed as

Anti-Inflammatory AgentsColchicineMetabolic SyndromeAdultBlood GlucoseC-Reactive ProteinFemaleHumansInsulinInsulin ResistanceMaleMiddle AgedObesityPilot ProjectsAnti-Inflammatory AgentsBlood GlucoseColchicineC-Reactive ProteinInsulinbeta-cell functioninflammationinsulin resistanceinsulin sensitivityobesity

Identifiers

PMID30869182
PMCPMC6570563
OpenAlexW2922497220

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.